Cargando…
Bisphosphonate conjugation enhances the bone-specificity of NELL-1-based systemic therapy for spaceflight-induced bone loss in mice
Microgravity-induced bone loss results in a 1% bone mineral density loss monthly and can be a mission critical factor in long-duration spaceflight. Biomolecular therapies with dual osteogenic and anti-resorptive functions are promising for treating extreme osteoporosis. We previously confirmed that...
Autores principales: | Ha, Pin, Kwak, Jin Hee, Zhang, Yulong, Shi, Jiayu, Tran, Luan, Liu, Timothy Pan, Pan, Hsin-Chuan, Lee, Samantha, Kim, Jong Kil, Chen, Eric, Shirazi-Fard, Yasaman, Stodieck, Louis S., Lin, Andy, Zheng, Zhong, Dong, Stella Nuo, Zhang, Xinli, Wu, Benjamin M., Ting, Kang, Soo, Chia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507033/ https://www.ncbi.nlm.nih.gov/pubmed/37723136 http://dx.doi.org/10.1038/s41526-023-00319-7 |
Ejemplares similares
-
Specific host metabolite and gut microbiome alterations are associated with bone loss during spaceflight
por: Bedree, Joseph K., et al.
Publicado: (2023) -
Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation
por: Tanjaya, Justine, et al.
Publicado: (2016) -
NELL-1 in the treatment of osteoporotic bone loss
por: James, Aaron W., et al.
Publicado: (2015) -
Author Correction: NELL-1 in the treatment of osteoporotic bone loss
por: James, Aaron W., et al.
Publicado: (2021) -
Bisphosphonate conjugation for bone specific drug targeting
por: Farrell, Kristen B., et al.
Publicado: (2018)